Filtered By:
Condition: Peripheral Vascular Disease (PVD)
Drug: Fortamet

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 37 results found since Jan 2013.

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Conclusions/interpretationThere remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming. Alternative approaches to reduce the uncertainty include the use of electronic health records in long-term pragmatic evaluations, inclusion of metformin in factorial trials, publication of cardiovascular outcome data from adverse event reporting in...
Source: Diabetologia - August 2, 2017 Category: Endocrinology Source Type: research

Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus
Abstract Type 2 diabetes increases the risk of developing cardiovascular (CV) complications such as myocardial infarction, heart failure, stroke, peripheral vascular disease, and CV-associated mortality. Strict glycemic control in diabetics has shown improvement in microvascular complications related to diabetes but has been unable to demonstrate major effects on macrovascular complications including myocardial infarction and stroke. Conventional therapies for diabetes that include insulin, metformin, sulfonylureas (SU), and alpha-glucosidase inhibitors have limited and/or controversial data on CV safety based on...
Source: Current Cardiology Reports - October 10, 2014 Category: Cardiology Source Type: research

Oral hypoglycemic agents and the development of non‐fatal cardiovascular events in patients with type 2 diabetes mellitus
ConclusionsT2DM patients taking metformin and glimepiride are at lowered risk of non‐fatal CV events than those taking glyburide. This article is protected by copyright. All rights reserved.
Source: Diabetes/Metabolism Research and Reviews - July 1, 2013 Category: Endocrinology Authors: Yi‐Chih Hung, Che‐Chen Lin, Tzu‐Yuan Wang, Man‐Ping Chang, Fung‐Chang Sung, Ching‐Chu Chen Tags: Research Article Source Type: research

Oral hypoglycaemic agents and the development of non‐fatal cardiovascular events in patients with type 2 diabetes mellitus
ConclusionsT2DM patients taking metformin and glimepiride are at lower risk of non‐fatal cardiovascular events than those taking glyburide. Copyright © 2013 John Wiley & Sons, Ltd.
Source: Diabetes/Metabolism Research and Reviews - November 14, 2013 Category: Endocrinology Authors: Yi‐Chih Hung, Che‐Chen Lin, Tzu‐Yuan Wang, Man‐Ping Chang, Fung‐Chang Sung, Ching‐Chu Chen Tags: Research Article Source Type: research

WITHDRAWN: Metformin monotherapy for type 2 diabetes mellitus.
CONCLUSIONS: Metformin may be the first therapeutic option in the diabetes mellitus type 2 with overweight or obesity, as it may prevent some vascular complications, and mortality. Metformin produces beneficial changes in glycaemia control, and moderated in weight, lipids, insulinaemia and diastolic blood pressure. Sulphonylureas, alpha-glucosidase inhibitors, thiazolidinediones, meglitinides, insulin, and diet fail to show more benefit for glycaemia control, body weight, or lipids, than metformin. PMID: 26421423 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - September 30, 2015 Category: Journals (General) Authors: Saenz A, Fernandez-Esteban I, Mataix A, Ausejo Segura M, Roqué I Figuls M, Moher D Tags: Cochrane Database Syst Rev Source Type: research

Leptin, cardiovascular diseases and type 2 diabetes mellitus.
Abstract Leptin, an adipokine that is implicated in the control of food intake via appetite suppression, may also stimulate oxidative stress, inflammation, thrombosis, arterial stiffness, angiogenesis and atherogenesis. These leptin-induced effects may predispose to the development of cardiovascular diseases. In the present review we discuss the evidence linking leptin levels with the presence, severity and/or prognosis of both coronary artery disease and non-cardiac vascular diseases such as stroke, carotid artery disease, peripheral artery disease (PAD) and abdominal aortic aneurysms (AAA) as well as with chroni...
Source: Acta Pharmacologica Sinica - June 7, 2018 Category: Drugs & Pharmacology Authors: Katsiki N, Mikhailidis DP, Banach M Tags: Acta Pharmacol Sin Source Type: research

GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection.
Authors: Bertoccini L, Baroni MG Abstract The risk of cardiovascular disease (CVD) (myocardial infarction, stroke, peripheral vascular disease) is twice in type 2 diabetes (T2D) patients compared to non-diabetic subjects. Furthermore, cardiovascular disease (CV) is the leading cause of death in patients with T2D.In the last years several clinical intervention studies with new anti-hyperglycaemic drugs have been published, and they have shown a positive effect on the reduction of mortality and cardiovascular risk in T2D patients. In particular, these studies evaluated sodium/glucose-2 cotransporter inhibitors (SGLT2...
Source: Advances in Experimental Medicine and Biology - February 9, 2020 Category: Research Tags: Adv Exp Med Biol Source Type: research

Serum uric acid and diabetes: from pathophysiology to cardiovascular disease.
Abstract Hyperuricemia, has been traditionally related to nephrolithiasis and gout. However, it has also been associated with the development of type 2 diabetes mellitus (T2DM) and cardiometabolic and cardiovascular diseases. Pathophysiologically, elevated serum uric acid (SUA) levels may be associated with abnormal lipid and glucose metabolism. In this narrative review, we consider the associations between hyperuricemia, hyperglycemia, atherosclerosis and thrombosis. Furthermore, we comment on the available evidence linking elevated SUA levels with the incidence and outcomes of coronary heart disease, stroke, per...
Source: Current Pharmaceutical Design - January 4, 2021 Category: Drugs & Pharmacology Authors: Katsiki N, Dimitriadis GD, Mikhailidis DP Tags: Curr Pharm Des Source Type: research

Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association
Circulation. 2021 Mar 29:CIR0000000000000961. doi: 10.1161/CIR.0000000000000961. Online ahead of print.ABSTRACTThis statement summarizes evidence that adverse pregnancy outcomes (APOs) such as hypertensive disorders of pregnancy, preterm delivery, gestational diabetes, small-for-gestational-age delivery, placental abruption, and pregnancy loss increase a woman's risk of developing cardiovascular disease (CVD) risk factors and of developing subsequent CVD (including fatal and nonfatal coronary heart disease, stroke, peripheral vascular disease, and heart failure). This statement highlights the importance of recognizing APOs...
Source: Circulation - March 29, 2021 Category: Cardiology Authors: Nisha I Parikh Juan M Gonzalez Cheryl A M Anderson Suzanne E Judd Kathryn M Rexrode Mark A Hlatky Erica P Gunderson Jennifer J Stuart Dhananjay Vaidya American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombos Source Type: research

Sex-disparities in risk factors and atherosclerosis cardiovascular disease in diabetic patients
Conclusion: Among diabetic people, compared to males, females had a higher comorbid burden but received less optimal treatment, which might partly explain their higher prevalence of composite ASCVD and CHD.PMID:33874831 | DOI:10.1080/00325481.2021.1917930
Source: Postgraduate Medicine - April 20, 2021 Category: Internal Medicine Authors: Yue Sun Dong Yan Lijuan Cui Guiping Li Yan Sun Zirui Hao Source Type: research

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
Bioinformation. 2021 Mar 31;17(3):413-423. doi: 10.6026/97320630017413. eCollection 2021.ABSTRACTIt is of interest to evaluate the clinical effectiveness and safety of vildagliptin as monotherapy and combination therapy of vildagliptin and metformin for the management of type 2 diabetes mellitus (T2DM) patients in Indian settings. The study included patients with T2DM (aged >18 years) receiving vildagliptin monotherapy and vildagliptin in combination with metformin therapy of various strengths. Data related to demographics, risk factors, medical history, glycated hemoglobin (HbA1c) levels, and medical therapies were ret...
Source: Bioinformation - June 7, 2021 Category: Bioinformatics Authors: Sambit Das A K Gupta Biplab Bandyopadhyaya B Harish Darla Vivek Arya Mahesh Abhyankar Santosh Revankar Source Type: research